An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate by Christopher Hautmann et al.
Hautmann et al. BMC Psychiatry 2013, 13:219
http://www.biomedcentral.com/1471-244X/13/219RESEARCH ARTICLE Open AccessAn observational study of response
heterogeneity in children with attention deficit
hyperactivity disorder following treatment switch
to modified-release methylphenidate
Christopher Hautmann1, Aribert Rothenberger2 and Manfred Döpfner1*Abstract
Background: Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficit
hyperactivity disorder (ADHD) in children. The overall population of children and adolescents with ADHD may
comprise distinct clusters of patients that differ in response to MPH. The aim of this analysis was to look for
subgroups with different treatment trajectories and to identify their distinctive features.
Methods: OBSEER was a prospective, observational study examining the effectiveness and safety of once-daily
modified-release MPH over 3 months in patients (aged 6–17 years) with ADHD under routine care. Assessments
were carried out at baseline (Visit 1), after 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) after first use of once-daily
modified-release MPH. Change in ADHD symptoms, as rated by parents and teachers, was examined post hoc in
patients of the intent-to-treat-population (N = 822), using growth-mixture modelling to detect response trajectory
groups after switching medication. Age, MPH dose at Visit 1 before medication switch, prescribed once-daily
modified-release MPH dose at Visits 1 and 2, conduct problems and emotional symptoms were considered
predictors of response subgroups.
Results: Assessing formal statistical criteria and usefulness of the models, a 4-class solution best fitted the data:
after switching medication two response groups with severe symptoms at study start and subsequent substantial
treatment effects, and two showing no or comparatively little treatment effect, one of which had severe and the
other less severe symptoms at study start. Patient age, conduct problems and MPH dose at Visit 1 were predictors
of inclusion in subgroups.
Conclusions: Older children and children with few conduct problems were more likely to be members of a patient
cluster with fewer symptoms at study start. Children with a low MPH dose before medication switch had a higher
chance of being in the patient cluster with a strong treatment response after switching medication. The current
analyses should assist in identifying children likely to achieve a favourable treatment course with MPH and,
additionally, those who are in need of alternative treatment options.
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For children with severe symptoms of attention deficit
hyperactivity disorder (ADHD), methylphenidate (MPH) is
one of the major treatment options. In randomized placebo-
controlled trials, MPH has been shown to be effective and
to be associated with, on average, large treatment effects
[1,2]. In addition to improving symptom control, MPH can
have favourable effects on comorbid oppositional symptoms
[3,4] and social functioning [5,6]. Side effects can occur and
may require adaptation of the treatment plan [7]. Because of
its efficacy and tolerability profile, MPH is recognized in
treatment guidelines in Europe and the USA [8-11].
The response achieved by drug treatment varies among
children with ADHD; some children will experience ad-
equate symptom control, whereas for others benefits will be
minor [12]. There is currently little information on response
prediction in ADHD, and detecting and explaining differen-
tial treatment effects should be considered an important
part of the general treatment research agenda [13,14].
Given the variation in responsiveness, it is reasonable to
suggest that the population of patients treated with MPH
is heterogeneous and may comprise distinct subgroups,
which could be identified. For example, in therapy-naïve
children receiving MPH for the first time, two subgroups
might be hypothesized to exist: responders, showing good
symptom reduction over time, and partial responders, who
show few or no treatment effects. Subpopulations can be
defined based on ‘observed’ variables that are directly
measureable characteristics (e.g., comorbidity). For ex-
ample, Ghuman et al. [15] found that comorbidities in
preschool children with ADHD predicted response to
MPH; the subgroup of children with three or more co-
morbid disorders did not respond to treatment com-
pared with those with two or fewer comorbidities.
Subgroups may not always be identifiable by ‘a priori’-
defined measureable characteristics and instead have to be
inferred from the data [16,17]. As in this case, group
membership is not known beforehand, so these subgroups
can be called ‘latent’ or ‘unobserved’ [18]. In clinical re-
search, there is growing interest in the detection of unob-
served subgroups associated with differential treatment
effects [19]. However, in the treatment of ADHD, know-
ledge in this area remains very limited. In analyses by
Sonuga-Barke et al. [20] of data from COMACS (Com-
parison of Methylphenidates in the Analog Classroom Set-
ting) [21] and by Swanson et al. [22] of data from the
MTA (Multimodal Treatment Study of Children with
ADHD) [23], subgroups could be identified and subgroup
membership could be linked to differential treatment ef-
fects. Owing to differences in methodology and study de-
sign, including varying observation periods of 12 hours
(COMACS) and 3 years (MTA), direct comparisons of the
results of these analyses are not meaningful. Nonetheless,
the conclusion from both studies was that, for symptomchange in children with ADHD, the overall population is
heterogeneous and it is reasonable to look for subgroups
with different treatment responses.
MPH is available in immediate-release and extended-
release formulations [24]. For immediate-release prepara-
tions, the average duration of action is about 4 hours;
extended-release formulations are designed to be effective
for 8–12 hours [25,26]. Several extended-release formula-
tions, with different compositions and pharmacokinetic
properties, are available [27,28]. Meta-analytical compari-
sons point to similar effect sizes for both delivery forms of
MPH [29]. As both immediate- and extended-release for-
mulations have advantages and disadvantages, treatment
guidelines often provide recommendations specifying which
delivery format is appropriate given a patient’s individual
circumstances [27].
Equasym XLW (Shire Pharmaceuticals Ireland Ltd) [30]
is a modified-release MPH (MR-MPH) formulation com-
prising 30% immediate-release coated beads and 70%
extended-release coated beads, delivering an initial rapid
rise in plasma concentration and a slower rise over about
3 hours, with therapeutic plasma concentrations and effi-
cacy in symptom reduction maintained for about 8 hours.
The safety profile and efficacy of MR-MPH have been
demonstrated in controlled clinical trials [31].
The OBSEER study (OBservation of Safety and Effective-
ness of Equasym XL in Routine care), a 3-month, prospect-
ive, observational study involving children and adolescents
with ADHD in Germany, was conducted under routine care
conditions to gain insights into the effectiveness and safety
of treatment with MR-MPH in everyday use. The study in-
cluded children and adolescents diagnosed with ADHD for
whom therapy with MR-MPH was already planned by the
attending physician. Patients could have a treatment history
with other MPH formulations, other drugs for ADHD or
non-pharmacological interventions, or could be treatment
naïve. In OBSEER, statistically significant treatment im-
provements in ADHD symptoms were seen from baseline
to last visit [32]. The effectiveness of MR-MPH was rated
better than prior therapy by both teachers and parents at all
measured time points across the day, particularly late morn-
ing and early afternoon.
The aim of the present analysis was twofold. First, to iden-
tify subgroups with different treatment response trajectories,
thereby extending previous work to attain a more complete
picture of response heterogeneity during treatment [20,22].
Second, to identify predictors of subgroups with differential
responsiveness that might allow physicians to better select
the appropriate treatment for an individual patient.
Methods
Participants
Patients aged 6–17 years with a confirmed diagnosis of
ADHD according to the Diagnostic and Statistical Manual
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[33] or hyperkinetic disorder (HKD) according to the Inter-
national Classification of Diseases, Version 10 (ICD 10) [34],
who were attending school and for whom therapy with
MR-MPH (10, 20 or 30 mg once daily) was indicated
and already intended by the attending physician, were eli-
gible to participate in the study. Exclusion criteria included
mental disability and contraindications for MR-MPH [30].
Study design
OBSEER was a non-interventional, uncontrolled, multi-
centre, prospective, observational study conducted in
169 centres in Germany. Written informed consent was
obtained from parents. As this was an open observa-
tional study under conditions of routine care, there was
no IRB-approval necessary according to German rules
and European regulations [35,36].
Participating physicians (specialists in paediatrics and/or
child and adolescent psychiatry) selected appropriate pa-
tients for whom therapy with MR-MPH was indicated.
The planned observation period for each patient was 6–12
weeks after the first use of MR-MPH and included three
visits: prior to the start of MR-MPH treatment (Visit 1),
and 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) after the
first use of MR-MPH in accordance with standard prac-
tice. On average, Visit 2 took place 3.5 weeks after Visit 1,
and Visit 3 took place 10.5 weeks after the start of the ob-
servational period. MR-MPH was prescribed for the first
time at Visit 1 and the dose was adjusted, when necessary,
at Visits 2 and 3. The study started on 2 November 2006;
inclusion of patients concluded on 28 February 2007, and
observation was completed on 27 December 2007 [32].
Assessments
The outcome variable used to describe the response trajectory
was the mean symptom score, calculated using the German
ADHD Symptom Checklist (Fremdbeurteilungsbogen für
Aufmerksamkeitsdefizit-Hyperaktivitätsstörung [FBB-ADHD]),
which is part of the German Diagnostic System for Mental
Disorders in Children and Adolescents (DISYPS) [37]. This
checklist assesses diagnostic criteria for ADHD according
to DSM-IV-TR and for HKD according to ICD-10. Twenty
items are rated on a 4-point scale (0–3), with higher scores
indicating more severe symptoms. The overall symptom
score (range 0–3) represents the sum of the individual item
scores divided by the number of items. Parents and
teachers rated items separately at each visit; the analyses
included information from both informants.
Several covariates were considered for the prediction
of subgroups of responsiveness: patient age; the daily
dose (mg) of MPH before switch to MR-MPH (MPHpre)
as recorded at Visit 1 (for MPHpre, patients receiving no
medication, or medication other than MPH, were assigned
the value 0); the daily dose (mg) of MR-MPH as recordedat Visit 1 (MPHVisit 1) and Visit 2 (MPHVisit 2); and the pa-
tient’s conduct problems (5 items) and emotional symp-
toms (5 items), as rated by parents at Visit 1 using the
Strengths and Difficulties Questionnaire (SDQ) [38] on a
scale of 0–2, with higher scores indicating more severe
symptoms and with scale scores representing the sum of
the individual item scores (range 0–10).
Statistical analysis
Growth mixture modelling [39,40] was applied to detect
subgroups with varying trajectories of change in ADHD
symptoms in parent and teacher ratings. For different infor-
mants, separate parallel growth processes were conceived
and one common categorical latent variable representing
subgroups was taken into account. Both growth models
had the same periodicity; separate growth rates were taken
into account from Visit 1 to Visit 2 and from Visit 2 to Visit
3 [41].
To detect distinctive features of the subgroups, the se-
lected covariates (age, MPHpre, MPHVisit 1, MPHVisit 2, con-
duct problems, emotional symptoms) were included in the
model as predictors (conditional growth mixture model).
Regression of a latent categorical variable on the covariates
represents a multinomial logistic regression analysis. All
covariates were z-transformed before being analysed. To
provide an explicit overview of the interrelationships be-
tween covariates and subgroups, unstandardized means
and standard deviations of covariates in the respective sub-
groups were calculated: values were obtained by weighting
raw data with the estimated posterior probabilities [42,43].
For the conditional growth mixture model, two to seven
classes were considered.
The target sample for analysis was the 822 evaluable
patients of the intent-to-treat population in OBSEER, as
described by Döpfner et al., previously [32]. For growth
mixture modelling, missing data were handled using the
full-information maximum-likelihood method (FIML)
[44,45] and the total sample of the intent-to-treat popu-
lation was considered. Models with up to seven classes
were considered. Model selection was based on a formal
statistical criterion, the Bayesian information criterion
[BIC] [46], as well as clinical considerations [19]. All
analyses were conducted using Mplus software [47].
Results
Study population
Evaluable patients in OBSEER (N = 822) had a mean
(standard deviation) age of 10.04 (2.47) years and 81.25%
(663/816) were male. Approximately half of the patients
(55.40%; 431/778) had a disturbance of activity and at-
tention (ICD code F90.0), which is similar to ADHD
combined type according to DSM-IV; 36.38% (283/778)
had a hyperkinetic conduct disorder (F90.1) and 8.23%
(64/778) had other hyperkinetic disorders (F90.8). Most
Table 1 Available sample sizes, means and standard




Visit 1 742 1.63 0.62
Visit 2 699 1.16 0.59
Visit 3 637 0.99 0.55
Teacher rating
Visit 1 570 1.29 0.70
Visit 2 522 1.00 0.61
Visit 3 489 0.85 0.57
Covariates
Age (years) 808 10.04 2.47
MPHpre (mg) 772 16.28 14.77
MPHVisit 1 (mg) 802 22.53 9.63
MPHVisit 2 (mg) 675 25.25 9.44
Conduct problemsa 721 4.16 2.29
Emotional symptomsb 722 3.79 2.46
ADHD = attention deficit hyperactivity disorder; MPH = methylphenidate;
MPHpre = daily dose of MPH before switch to modified-release MPH;
MPHVisit 1 = daily dose of modified-release MPH prescribed at Visit 1;
MPHVisit 2 = daily dose of modified-release MPH prescribed at Visit 2;
SD = standard deviation.
aConduct Problems Scale Strengths and Difficulties Questionnaire in parent
ratings at Visit 1.
bEmotional Symptoms Scale Strengths and Difficulties Questionnaire in parent
ratings at Visit 1.
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MPH formulations; among whom 35.37% (203/574) were
previously prescribed extended-release MPH formula-
tions. One quarter of patients (25.30%; 208/822) were
treatment naïve; only 4.87% (40/822) received other medi-
cations (e.g., atomoxetine, amphetamine) or no medica-
tion was specified. Among those previously receiving
treatment, the main reasons for switching medication
were insufficient overall effectiveness and/or the duration
of effect was too short.
Growth mixture model analysis
Available sample sizes, means and standard deviations for
outcome-variable ADHD symptoms and covariates of the
growth mixture models are presented in Table 1. A de-
cline in parent-rated and teacher-rated ADHD symptoms
was observed in the total study group over the course of
the study. The statistical significance of this symptom re-
duction has already been discussed elsewhere [32]. Mean
daily MPH dose was lowest before the switch to MR-
MPH and increased from Visit 1 to Visit 2.
All conditional growth mixture models converged; BIC
values from the two-class solution through to the seven-
class solution were 17,201, 17,104, 17,075, 17,064, 17,068
and 17,067, respectively. According to the BIC, the best fit
was the five-class solution, but closer inspection revealed a
subgroup containing only about 3% of the sample.
Assessing formal statistical criteria, and the parsimonious-
ness and usefulness of the models, the four-class solution
was considered to be optimal; subgroup trajectories for this
solution are presented for parent (Figure 1) and teacher
(Figure 2) ratings. The subgroups identified included one
with low symptom scores at Visit 1 (low-start group) and
three with higher initial symptom scores (high-start
groups). Additionally, subgroups were also divided into
those in which symptoms decreased between Visits 1 and
2 with little or no change between Visits 2 and 3 in either
parent or teacher ratings (first-phase response); those in
which symptoms decreased between Visits 1 and 2 for the
parent rating scales and between Visits 2 and 3 for teacher
scales (mixed-response); and those in which there were
minor changes in symptom scores during the observation
period (low-response).
The strongest treatment effects were observed in two
of the high-start groups. In the first group (high-start,
first-phase response), which included 18.7% (n = 154) of
all patients, both parents and teachers reported a symp-
tom decrease from Visit 1 to Visit 2, with no or little
change from Visit 2 to Visit 3. In the second, smaller,
high-start group (high-start, mixed-response), which in-
cluded only 6.0% (n = 49) of all patients, both infor-
mants reported strong symptom reduction, but the time
during which the change was perceived differed, with
the greatest improvement perceived from Visit 1 to Visit 2for teachers and from Visit 2 to Visit 3 for parents. In the
third high-start group (high-start, low-response), which
included 27.7% (n = 227) of all patients, no or only a mod-
est change was observed in both parent and teacher rat-
ings. Similarly, for the low-start, low-response group,
which was the largest subgroup with 47.7% (n = 392) of all
patients, only minor changes in symptom scores were
seen during the observation period.
In comparison with the total sample, children from the
high-start, mixed-response and high-start, first-phase re-
sponse groups could be described as younger, receiving a
lower dose of MPH before study start, receiving a lower
dose of MR-MPH at Visits 1 and 2, and showing more se-
vere conduct problems and an average level of emotional
symptoms (Table 2). Similarly, children in the high-start,
low-response group could be characterized as being of
average age, receiving an average or slightly above-average
dose of MPH before study start, receiving an average dose
of MR-MPH at Visits 1 and 2, and demonstrating higher
than average conduct problems and pronounced emotional
symptoms (Table 2). Children in the low-start group were
older, were prescribed average MPH doses before study
start, received average doses of MR-MPH at Visits 1 and 2,
and exhibited minor conduct problems and an average

















3.0 High-start, mixed-response, 6.0%
High-start, first-phase response, 18.7%
High-start, low-response, 27.7%
Low-start, low-response, 47.7%
Figure 1 ADHD symptom trajectories in parent ratings. ADHD symptom trajectories in parent ratings from Visit 1 to Visit 3 in the four-class
solution of the conditional growth mixture model (N = 822); time corresponds to the average time the visits took place. ADHD = attention deficit
hyperactivity disorder; FBB-ADHD = German ADHD Symptom Checklist (Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitäts
störung). High-start = subgroups with more severe symptoms compared with the low-start group at Visit 1; mixed-response = in parent ratings,
comparatively stronger treatment response is observed during Visit 2 to Visit 3 and in teacher ratings during Visit 1 to Visit 2; first-phase response =
in parent and in teacher ratings comparatively stronger treatment response is observed during Visit 1 to Visit 2; low-response = compared with
other subgroups, only minor symptom reduction is detected during the observational period.
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using the multinomial logistic regression analysis, which
provides a statistical test for the significance of a particular
covariate while controlling for all other predictor variables
(Table 3). Age could be used to discriminate the low-start
subgroup from all other subgroups: as age increased, so did
the probability of inclusion in the low-start subgroup. MPH
dose at pretreatment (MPHpre) could discriminate between
the two subgroups with good treatment response (high-
















Figure 2 ADHD symptom trajectories in teacher ratings. ADHD sympto
solution of the conditional growth mixture model (N = 822); time correspo
hyperactivity disorder; FBB-ADHD = German ADHD Symptom Checklist (Fre
störung). High-start = subgroups with more severe symptoms compared w
comparatively stronger treatment response is observed during Visit 2 to Vis
in parent and in teacher ratings comparatively stronger treatment response
other subgroups only minor symptom reduction is detected during the obsthe two subgroups with little or no treatment response
after switching medication (high-start, low-response; low-
start, low-response), with higher pretreatment doses in-
creasing the likelihood of falling into one of the less
responsive subgroups. The prescribed dose of MR-MPH
at Visit 1 (MPHVisit 1) and Visit 2 (MPHVisit 2), and emo-
tional symptom scores were not useful for subgroup pre-
diction in either class comparison. Conduct problems,
however, showed predictive power, with greater conduct
problems reducing the likelihood of inclusion in theeeks
10.5
High-start, mixed-response, 6.0%
High-start, first-phase response, 18.7%
High-start, low-response, 27.7%
Low-start, low-response, 47.7%
m trajectories in teacher ratings from Visit 1 to Visit 3 in the four-class
nds to the average time the visits took place. ADHD = attention deficit
mdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitäts
ith the low-start group at Visit 1; mixed-response = in parent ratings,
it 3 and in teacher ratings during Visit 1 to Visit 2; first-phase response =
is observed during Visit 1 to Visit 2; low-response = compared with
ervational period.





response (n = 49)
High-start, first-phase
response (n = 154)
High-start, low-
response (n = 227)
Low-start, low-
response (n = 392)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (years) 10.04 (2.47) 8.83 (2.33) 9.26 (2.29) 9.96 (2.51) 10.55 (2.38)
MPHpre (mg) 16.45 (14.80) 6.27 (10.39) 9.57 (12.29) 19.42 (15.03) 18.39 (14.61)
MPHVisit 1 (mg) 22.51 (9.61) 17.41 (7.81) 19.82 (7.97) 23.00 (10.61) 24.00 (9.38)
MPHVisit 2 (mg) 25.52 (9.81) 21.61 (7.47) 23.26 (7.89) 26.10 (11.18) 26.03 (8.90)
Conduct problemsa 4.16 (2.29) 6.67 (1.84) 5.43 (1.90) 5.17 (2.04) 2.77 (1.67)
Emotional symptomsb 3.79 (2.46) 3.78 (2.47) 3.55 (2.51) 4.48 (2.38) 3.48 (2.41)
High-start = subgroups with more severe symptoms compared with the low-start group at Visit 1; mixed-response = in parent ratings, comparatively stronger
treatment response is observed during Visit 2 to Visit 3 and in teacher ratings during Visit 1 to Visit 2; first-phase response = in parent and in teacher ratings
comparatively stronger treatment response is observed during Visit 1 to Visit 2; low-response = compared with other subgroups only minor symptom reduction is
detected during the observational period; Missing data were handled by FIML; to obtain means and SDs in the subgroups, raw data were weighted by the
estimated posterior probabilities.
FIML = full-information maximum-likelihood method; MPH =methylphenidate; MPHpre = daily dose of MPH before switch to modified-release MPH; MPHVisit 1 =
daily dose of modified-release MPH prescribed at Visit 1; MPHVisit 2 = daily dose of modified-release MPH prescribed at Visit 2; SD = standard deviation.
aConduct Problems Scale Strengths and Difficulties Questionnaire in parent ratings at Visit 1.
bEmotional Symptoms Scale Strengths and Difficulties Questionnaire in parent ratings at Visit 1.
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groups with higher ADHD symptom scores at study start,
higher conduct problem scores increased the likelihood of
inclusion in the high-start, mixed-response subgroup.Discussion
Treatment response to MPH is variable, supporting the
contention that the population of children receiving treat-
ment for ADHD is not homogeneous. This analysis sought
to identify and determine the distinctive features of clusters
















β OR β OR β
Age (years) –0.85a 0.43 –0.65a 0.52 –0.39a
MPHpre (mg) –1.18
a 0.31 –0.73a 0.48 0.11
MPHVisit 1 (mg) –0.13 0.88 0.03 1.03 –0.15
MPHVisit 2 (mg) –0.07 0.94 –0.02 0.98 0.06
Conduct problemsb 2.80a 16.40 1.93a 6.92 1.60a
Emotional symptomsc –0.31 0.73 –0.26 0.77 0.17
High-start = subgroups with more severe symptoms compared with the low-start gr
treatment response is observed during Visit 2 to Visit 3 and in teacher rating during
comparatively stronger treatment response is observed during Visit 1 to Visit 2; low
detected during the observational period; for analyses, all covariates were z-transfo
β = regression coefficient; OR = odds ratio; MPH =methylphenidate; MPHpre = daily d
modified-release MPH prescribed at Visit 1; MPHVisit 2 = daily dose of modified-relea
aα < 0.05.
bConduct Problems Scale Strengths and Difficulties Questionnaire in parent ratings
cEmotional Symptoms Scale Strengths and Difficulties Questionnaire in parent ratinwith MR-MPH in parent and teacher ratings under real
world conditions using data from the OBSEER study [32].
After switching medication, four response subgroups
were detected: two with substantial treatment effects,
both of which had more severe symptoms at study start,
and two with little or no treatment effects, one of which
had low initial symptom scores and one that had more
severe symptoms at study start.
The subgroup with low initial symptom scores was the
largest, comprising about half of all children. Here, only
small treatment effects were observed, and for adequate





















OR β OR β OR β OR
0.68 –0.46 0.63 –0.26 0.77 –0.20 0.82
1.12 –1.29a 0.28 –0.84a 0.43 –0.46 0.63
0.87 0.02 1.02 0.18 1.19 –0.16 0.85
1.06 –0.12 0.88 –0.08 0.92 –0.04 0.96
4.97 1.19a 3.29 0.33 1.39 0.87a 2.38
1.18 –0.48 0.62 –0.42 0.66 –0.06 0.95
oup at Visit 1; mixed-response = in parent ratings, comparatively stronger
Visit 1 to Visit 2; first-phase response = in parent and in teacher ratings
-response = compared with other subgroups only minor symptom reduction is
rmed.
ose of MPH before switch to modified-release MPH; MPHVisit 1 = daily dose of
se MPH prescribed at Visit 2.
at Visit 1.
gs at Visit 1.
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have reached good symptom control with the previous
medication, leaving relatively little room for symptom im-
provement with transition to MR-MPH. In this study, the
meaning of the term treatment response is therefore to
understand the response following the change in treat-
ment relative to previous medication effects and is no in-
dication for absolute efficacy of MR-MPH. However, some
symptom reduction was observed in this group. On a de-
scriptive level, children in the low-start subgroup were
older and had fewer conduct problems. Statistical tests
confirmed that age and conduct problems were useful
predictors to distinguish the low-start subgroup from the
other groups, which concurs with previous research find-
ings. Generally, it is accepted that ADHD symptoms de-
crease with age, although the finding of symptom
reduction with age may reflect the developmental insensi-
tivity of the DSM-IV, not the natural history of ADHD
[48], and that children without comorbid conduct prob-
lems generally exhibit fewer ADHD symptoms than their
counterparts with such comorbidities [49].
Approximately one quarter of the children fell into one
of two subgroups with a strong response to MR-MPH.
One feature distinguishing the two more responsive sub-
groups from the two more stable subgroups was the MPH
dose at study start. On a descriptive level, children in the
more-responsive groups were treated less intensively prior
to study start; statistical analysis confirmed that lower
MPH dose before medication switch was linked to a higher
probability of falling into a more-responsive subgroup. Due
to the fact that the premedication in the more-responsive
subgroups was lower than that in the less-responsive sub-
groups, the relative increase in MPH dosage in these
groups was the highest after the medication switch. These
findings are in line with the assumption of a linear dose–
response relationship between MPH treatment and ADHD
symptoms, as has previously been demonstrated [50,51].
However, more-responsive versus low-response subgroups
could not be distinguished by the prescribed MR-MPH
doses during the observation period.
One third of children were classified as ‘high-start, low-
response’, with higher initial symptom scores and no or
only modest treatment effects after switch to MR-MPH.
These children represent a population that is difficult to
treat. The average MPH dose was about 19 mg/day at
study start and 26 mg/day at Visit 2 for this subgroup. For
patients in this cluster, adjustment or change of medication
or additional psychosocial interventions should be consid-
ered [52,53].
Emotional symptoms were not useful for distinguishing
between subgroups. Early work addressing the importance
of anxiety on the effect of stimulant medication in ADHD
indicated that behavioural effects are weaker in anxious
children [54]. From this conclusion, for the current analysis,it would have been expected that more anxious children
would be less likely to be in one of the more-responsive
groups. However, more recent studies have not replicated
these findings [55,56], and Tannock [57] suggests that
current evidence points to similar effects of stimulant
medication in children with and without comorbid anx-
iety. The current analysis is in line with this evaluation.
Conduct problems proved to be useful for distinguishing
subgroups with more-severe ADHD symptoms from the
subgroup with less-severe symptoms at study start, but
this variable was less suited to differentiating between sub-
groups with and without a good treatment response after
switching medication. Connor et al. [3] suggest that the ef-
fects of pharmacotherapy are similar in children with
ADHD, both with and without comorbid conduct prob-
lems, which corresponds with our findings.
In OBSEER, Döpfner et al. [58] reported that treatment-
naïve as well as pretreated children demonstrated ADHD
symptom reduction during the observational period of the
study, and that the greatest reduction was seen in
treatment-naïve patients. In the present analysis, these two
groups were not explicitly distinguished, but it was found
that less-intensively pretreated children were more likely to
be members of one of the two response subgroups, which
is in line with the previous analysis.
The advancement of evidence-based medicine has had a
major impact on the healthcare system and intervention
research [59,60]. High quality studies are required to dem-
onstrate the efficacy of a particular treatment [61]. The
quality of evidence from clinical studies varies depending
on the study design and, in general, evidence from ran-
domized, controlled trials is considered to be of high qual-
ity and that from observational studies is sometimes
considered to be of low quality [62]. Nevertheless, both re-
search designs have strengths and limitations, and instead
of regarding them in a strictly hierarchical fashion, with
randomized, controlled trials as the gold standard, a differ-
ent perspective is to view them as complementary re-
search designs [63,64]. Randomized, controlled trials are
high on internal validity but there may be a lack of
generalizability of their findings. For example, in the
MTA, the largest clinical trial in ADHD to date, children
with irregular school visits were not eligible for participa-
tion and the generalizability of study findings for these
children is unclear [23]. While the possibility for drawing
causal inferences about the reasons for symptom reduc-
tion is limited in observational trials, they can provide
valuable information regarding whether a treatment is
likely to be effective under real world conditions, across
different patient types and settings.
Because this was an observational study it has specific
strengths and limitations. The pre-study medication
history of the children evaluated in the study was var-
ied, with the majority of children switching from other
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no baseline medication/dose stabilization phase. Fur-
thermore, administration of MPH did not follow a stan-
dardized treatment protocol and treatment plans were
individualized. Differences in symptomatology, previ-
ous medication and actual medication are therefore
confounded and interpretation of treatment effects is
complicated. Low internal validity is one of the major
drawbacks of observational studies. However, this ana-
lysis identifies clusters of patients that can be observed
in common medical practice. Information about a pa-
tient’s initial situation and ADHD treatment in real
world settings, including treatment regimes and treat-
ment responses, is valuable for clinical practice as well
as research. For the practitioner, knowledge about the
typical subgroups of patients in routine clinical practice
may be useful for treatment individualization. Further-
more, such studies are useful to show the need for
treatment optimization.
There were several limitations to this study. First, this
was an observational study with no (placebo) control
group and parents were not blinded to the study treat-
ment or dose, which may have influenced parent-ratings
of ADHD symptoms. The use of a placebo control group
would have allowed us to disentangle actual perceived
improvements from bias based on hope or expectations
of the parents. Yet, teachers were not formally informed
of the change of treatment, and although they could
have been told by parents or children, most were not
aware. Second, the results for the previously treated
group can only be generalized to a population in which
a switch to MR-MPH is planned due to suboptimal effi-
cacy with prior medication. Third, in particular for
teacher ratings of ADHD symptoms, there was a sub-
stantial proportion of missing data. For this analysis, an
inclusive missing data handling strategy was used and all
available data were taken into account. Even when the
underlying assumptions of such strategies are not met,
they are still considered to be an improvement over ad
hoc procedures like listwise deletion [65]. Advantages of
this study are the relatively long period of observation,
the large sample size and the use of multiple informants.
Conclusions
Together with those by Sonuga-Barke et al. [20] and
Swanson et al. [22], this is one of the few studies that has
investigated the presence of latent subgroups in patients
with ADHD with varying treatment responses after medi-
cation with MPH. All three studies indicate that there is
heterogeneity in treatment response. The total population
of children with ADHD – either previously treated or
treatment naïve – receiving modified-release MPH under
routine care conditions is best conceived as a composite of
distinct subpopulations with varying treatment responses.The current analysis revealed four subgroups after
switching medication. Distinctive features of subgroups
could be identified. Age, MPH dose at study start and
conduct problems were particularly useful to discrimin-
ate between clusters of patients. Older children and
children with few conduct problems were more likely
to be members of a patient cluster with few symptoms
at study start. Children with a low MPH dose in the be-
ginning had a higher chance of being in the patient
cluster with a strong treatment response. These results
were in line with expectations. More research is needed
to replicate these findings and to explore additional
predictors to achieve a more complete picture of the
differentiating characteristics of responsiveness sub-
groups. The current analyses should assist in identify-
ing children likely to achieve a favourable treatment
course with MPH and, additionally, those who are in
need of alternative treatment options.
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